$PULM
Pulmatrix, Inc. Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000119312517248241 Filed on August 04, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$335.0K	$0.00	$260.0K
YoY Change	449.18%	-100.0%	52.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.020M	$2.070M	$2.210M
YoY Change	30.32%	-6.33%	-77.63%
% of Gross Profit
Research & Development	$2.618M	$3.363M	$2.441M
YoY Change	73.72%	37.77%	51.61%
% of Gross Profit
Depreciation & Amortization	$60.00K	$70.00K	$60.00K
YoY Change	0.0%	16.67%	-50.0%
% of Gross Profit
Operating Expenses	$4.639M	$5.429M	$9.230M
YoY Change	51.75%	-41.18%	-19.66%
Operating Profit	-$4.304M	-$5.429M	-$8.970M
YoY Change	43.66%	-39.48%	-20.75%
Interest Expense	$153.0K	$172.0K	$224.0K
YoY Change	-32.0%	-23.21%	-31.5%
% of Operating Profit
Other Income/Expense, Net	$5.000K	$4.000K	$7.000K
YoY Change	-92.19%	-42.86%	-75.86%
Pretax Income	-$4.450M	-$5.600M	-$9.190M
YoY Change	40.82%	-39.06%	-38.32%
Income Tax
% Of Pretax Income
Net Earnings	-$4.452M	-$5.597M	-$9.187M
YoY Change	41.02%	-39.08%	-38.33%
Net Earnings / Revenue	-1328.96%		-3533.46%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.203M	-$2.857M	-$6.209M
COMMON SHARES
Basic Shares Outstanding	20.12M shares	19.07M shares	14.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.360M	$10.98M	$10.79M
YoY Change	-13.0%	1.76%	-57.7%
Cash & Equivalents	$6.360M	$10.98M	$10.79M
Short-Term Investments
Other Short-Term Assets	$890.0K	$750.0K	$206.0K
YoY Change	332.04%	264.08%	-59.61%
Inventory
Prepaid Expenses
Receivables	$305.0K
Other Receivables	$0.00
Total Short-Term Assets	$7.550M	$11.73M	$11.80M
YoY Change	-9.42%	-0.58%	-54.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$657.0K	$672.0K	$875.0K
YoY Change	-34.23%	-23.2%	60.55%
Goodwill	$10.91M	$10.91M	$15.94M
YoY Change	-31.54%	-31.54%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	809.09%
Total Long-Term Assets	$11.78M	$11.79M	$17.02M
YoY Change	-31.32%	-30.73%	-29.94%
TOTAL ASSETS
Total Short-Term Assets	$7.550M	$11.73M	$11.80M
Total Long-Term Assets	$11.78M	$11.79M	$17.02M
Total Assets	$19.33M	$23.52M	$28.82M
YoY Change	-24.16%	-18.39%	-42.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.027M	$564.0K	$664.0K
YoY Change	156.11%	-15.06%	111.46%
Accrued Expenses	$1.587M	$2.583M	$1.212M
YoY Change	33.03%	113.12%	19.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.896M	$2.745M	$2.233M
YoY Change	55.16%	22.93%
Total Short-Term Liabilities	$6.510M	$5.892M	$4.109M
YoY Change	58.59%	43.39%	209.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.804M	$4.548M
YoY Change	-100.0%	-60.33%	-32.18%
Other Long-Term Liabilities	$40.00K	$40.00K	$10.00K
YoY Change	300.0%	300.0%	0.0%
Total Long-Term Liabilities	$40.00K	$1.804M	$4.548M
YoY Change	-98.97%	-60.33%	-32.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.510M	$5.892M	$4.109M
Total Long-Term Liabilities	$40.00K	$1.804M	$4.548M
Total Liabilities	$6.545M	$7.731M	$8.668M
YoY Change	-18.28%	-10.81%	-21.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.5M	-$165.0M	-$143.0M
YoY Change	15.99%	15.44%	20.5%
Common Stock	$182.3M	$180.8M	$163.1M
YoY Change	11.41%	10.85%	3.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.78M	$15.79M	$20.15M
YoY Change
Total Liabilities & Shareholders Equity	$19.33M	$23.52M	$28.82M
YoY Change	-24.16%	-18.39%	-42.72%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$4.452M	-$5.597M	-$9.187M
YoY Change	41.02%	-39.08%	-38.33%
Depreciation, Depletion And Amortization	$60.00K	$70.00K	$60.00K
YoY Change	0.0%	16.67%	-50.0%
Cash From Operating Activities	-$4.620M	-$3.660M	-$3.860M
YoY Change	65.0%	-5.18%	-36.51%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$10.00K	-$100.0K
YoY Change	-88.89%	-90.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$30.00K	-$10.00K	-$100.0K
YoY Change	-88.89%	-90.0%	-101.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	4.110M	0.000
YoY Change	-104.88%		-100.0%
NET CHANGE
Cash From Operating Activities	-4.620M	-3.660M	-3.860M
Cash From Investing Activities	-30.00K	-10.00K	-100.0K
Cash From Financing Activities	20.00K	4.110M	0.000
Net Change In Cash	-4.630M	440.0K	-3.960M
YoY Change	33.05%	-111.11%	-115.8%
FREE CASH FLOW
Cash From Operating Activities	-$4.620M	-$3.660M	-$3.860M
Capital Expenditures	-$30.00K	-$10.00K	-$100.0K
Free Cash Flow	-$4.590M	-$3.650M	-$3.760M
YoY Change	81.42%	-2.93%	-37.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20124411	shares
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	35000
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5489000
CY2017Q2	us-gaap	Goodwill Goodwill	10914000
CY2017Q2	us-gaap	Liabilities Liabilities	7731000
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23520000
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5892000
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2745000
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1804000
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	63000
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	676000
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2344000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10788000
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2583000
CY2017Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	95000
CY2017Q2	us-gaap	Assets Current AssetsCurrent	11730000
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	180813000
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	564000
CY2017Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	517000
CY2017Q2	us-gaap	Assets Assets	23520000
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10976000
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20124411	shares
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20124411	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	57000
CY2017Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4549000
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	82000
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	654000
CY2017Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	156000
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	698000
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	316000
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	754000
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Prepaid Insurance PrepaidInsurance	355000
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	672000
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165026000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	500474	shares
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	158000
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	796000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	164706000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	747000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.14
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	173000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3276373	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	173000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1543214	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.05
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3325806	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.16
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	15789000
CY2017Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8000
CY2017Q2	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	243000
CY2017Q2	pulm	Debt Instrument Accretion Of Debt Discount DebtInstrumentAccretionOfDebtDiscount	54000
CY2017Q2	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	195000
CY2017Q2	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	1505000
CY2017Q2	pulm	Working Capital WorkingCapital	5838000
CY2017Q2	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	151000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18902000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1317000
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	54000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	4759000
CY2016Q4	us-gaap	Assets Assets	16663000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4182000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14850526	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14850526	shares
CY2016Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	206000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	46000
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5803000
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	136000
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	107000
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	35000
CY2016Q4	us-gaap	Goodwill Goodwill	10914000
CY2016Q4	us-gaap	Liabilities Liabilities	7902000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16663000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4650000
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2586000
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3217000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13000
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	58000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	577000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	197000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	786000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155946000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2829301	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.89
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	8761000
CY2016Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	15000
CY2016Q4	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	9000
CY2016Q4	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	155000
CY2016Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	202000
CY2016Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	51000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7000
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>2. Basis of Presentation</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and six months ended June 30, 2017, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2017. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2016, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 10, 2017.</p> </div>
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6794000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	7000
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	1315000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	127000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Entity Registrant Name EntityRegistrantName	Pulmatrix, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3706000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1215000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-183000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177000
	us-gaap	Interest Expense InterestExpense	359000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6649000
	us-gaap	Operating Expenses OperatingExpenses	8741000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13456000
	us-gaap	Net Income Loss NetIncomeLoss	-9080000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8741000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14467000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	304000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1315000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5035000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18179951	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1337000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	81425	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y0M15D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y0M26D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.41
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y0M15D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
	dei	Trading Symbol TradingSymbol	PULM
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	716355	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	138425	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the fair value of net assets acquired in business combinations, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</p> </div>
	pulm	Noncash Rent Expense NoncashRentExpense	11000
	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-9080000
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	94000
	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	35000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8114000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	8000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	117000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4623000
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	4575000
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-46000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-347000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-561000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-550000
	us-gaap	Interest Expense InterestExpense	448000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-172000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7942000
	us-gaap	Operating Expenses OperatingExpenses	15069000
	us-gaap	Net Income Loss NetIncomeLoss	-14857000
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	135000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14413000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5871000
	us-gaap	Revenues Revenues	656000
	us-gaap	Share Based Compensation ShareBasedCompensation	2402000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14779244	shares
	pulm	Impairment Of Intangible Assets Excluding Goodwill After Tax ImpairmentOfIntangibleAssetsExcludingGoodwillAfterTax	4575000
	pulm	Noncash Rent Expense NoncashRentExpense	22000
	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-14857000
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	103000
CY2015	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	11000
CY2016	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	35000
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2214000
CY2016Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	4575000
CY2016Q2	us-gaap	Interest Expense InterestExpense	224000
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	9230000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-9187000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8970000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2441000
CY2016Q2	us-gaap	Revenues Revenues	260000
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1169000
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14804606	shares
CY2016Q2	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-9187000
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2066000
CY2017Q2	us-gaap	Interest Expense InterestExpense	172000
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5429000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5597000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5429000
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3363000
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	709000
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19553281	shares
CY2017Q2	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-5597000

Files In Submission

Name	View Source	Status
0001193125-17-248241-index-headers.html	Edgar Link	pending
0001193125-17-248241-index.html	Edgar Link	pending
0001193125-17-248241.txt	Edgar Link	pending
0001193125-17-248241-xbrl.zip	Edgar Link	pending
d419563d10q.htm	Edgar Link	pending
d419563dex101.htm	Edgar Link	pending
d419563dex311.htm	Edgar Link	pending
d419563dex312.htm	Edgar Link	pending
d419563dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g419563snap1.jpg	Edgar Link	pending
pulm-20170630.xml	Edgar Link	completed
pulm-20170630.xsd	Edgar Link	pending
pulm-20170630_cal.xml	Edgar Link	unprocessable
pulm-20170630_def.xml	Edgar Link	unprocessable
pulm-20170630_lab.xml	Edgar Link	unprocessable
pulm-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix, Inc. Stock $pulm

2017 Q3 Form 10-Q Financial Statement

#000119312517248241 Filed on August 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix, Inc. Stock $pulm

2017 Q3 Form 10-Q Financial Statement

#000119312517248241 Filed on August 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix, Inc. Stock $pulm